Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Myelodysplastic Syndromes 25Recurrence 18Multiple Myeloma 17Lymphoma, Non-Hodgkin 14Lymphoma, B-Cell 14Lymphoma 14Leukemia, Lymphocytic, Chronic, B-Cell 13Ovarian Neoplasms 12Hematologic Neoplasms 12Pancreatic Neoplasms 10Melanoma 10Leukemia 9Hodgkin Disease 9Burkitt Lymphoma 9Stomach Neoplasms 8Myeloproliferative Disorders 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 7Leukemia, Biphenotypic, Acute 7Colorectal Neoplasms 7Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Breast Neoplasms 6

Interventions

venetoclax 1fludarabine 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Venentoclax × fludarabine × 90 days × Clear all
NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

First Affiliated Hospital of Zhejiang University

Phase 3 Recruiting
186 enrolled
Other neoplasm

Venentoclax

Data powered by HemOnc (CC BY 4.0) Colophon âš¡